To view this complimentary session, please scroll down and click “play” using the white triangle.
Following the session, please provide feedback using the “provide feedback” button. Your insights will help elevate future sessions, while also being informative to the speaker(s) and organizing committee.
Dr. Colleen Strain sits down with Paul Epner to tackle the topic of the value of laboratory medicine as a profession and the concept of becoming a power user of the laboratory.
Manager, Scientific Leadership and Education, Core Diagnostics
Colleen Strain, PhD is a Scientific Manager for Global Scientific Leadership and Education at Abbott. She is also on the scientific lead for the UNIVANTS of Healthcare Excellence program and lead for the Executive Leadership Exchange program. As a champion for laboratory medicine, Colleen is passionate about driving healthcare excellence through scientific collaborations and partnerships, while maximizing value within healthcare.
Colleen’s professional and education focus on the strategic value of laboratory medicine within healthcare. Colleen is a corporate representative on the International Federations of Clinical Chemistry (IFCC)– Task Force on Outcome Studies in Laboratory Medicine and actively supports the IFCC Task Force for Corporate Members.
Colleen Strain reported the following relevant financial disclosures:
• Salary: Abbott
• Stocks/Bonds: Abbott
Sepsis Alliance, USA
Paul L. Epner, MBA, MEd is a strategic problem-solver focused on improving patient outcomes especially through a focus on the process of diagnosis and on the clinical laboratory. After a 31-year career at Abbott Diagnostics across three countries that included the creation and directing of Abbott’s Labs are Vital program, he co-founded the nonprofit Society to Improve Diagnosis in Medicine (SIDM) and led the organization as CEO until stepping down in late 2021 after ten years. During his tenure, he created and chaired the Coalition to Improve Diagnosis, served as a member of the National Steering Committee for Patient Safety, and was a member of the National Quality Forum’s 2021 Leadership Consortium. Following his retirement from SIDM in 2021, he joined the Board of Directors of Sepsis Alliance and most recently was elected to be Vice-Chair of the Board. Additionally, he is a co-investigator on a four-year AHRQ-funded research effort to study the root causes of delayed cancer diagnosis and to develop strategies for mitigating them. Previously, he served on the Board of the Clinical Laboratory Management Association (CLMA) serving as President for 2 years and on multiple programs at the Centers for Disease Control and Prevention.
Paul Epner reported the following relevant financial disclosures:
• Consultant Fee: Abbott